(LGND) Ligand Pharmaceuticals Incorporated BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LGND) Ligand Pharmaceuticals Incorporated Complete Analysis Pack
Download Your Competitive Advantage
This Ligand Pharmaceuticals Incorporated BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Rylaze, ALL/LBL
Rylaze is Ligand's key hematology Star: it is approved for acute lymphoblastic leukemia and lymphoblastic lymphoma in patients 1 month and older, a niche with ongoing clinical need. Its use is tied to asparaginase replacement after allergy issues, so demand stays specialized and support-heavy. That fits a high-growth, high-touch Star profile.
Pneumosil, pediatric pneumococcal vaccine
Pneumosil is a WHO-prequalified 10-valent pneumococcal conjugate vaccine for children, which gives Ligand Pharmaceuticals Incorporated exposure to a large global prevention market. Demand is strongest in emerging countries, where pneumococcal disease burden stays high and public immunization programs keep expanding. Continued rollout and access support make it fit Star-like growth potential in the BCG Matrix.
Vaxneuvance, 15-valent pneumococcal vaccine
Vaxneuvance is a 15-valent pneumococcal conjugate vaccine with 15 serotypes, aimed at adults at risk, especially 65+. Pneumococcal disease still causes about 1.5 million deaths a year worldwide, so demand stays durable. For Ligand Pharmaceuticals Incorporated, that kind of broad, repeat immunization need supports a Star-style profile as commercial use expands.
Captisol platform
Captisol is Ligand Pharmaceuticals Incorporated’s proprietary enabling platform, used in multiple approved injectable medicines and tied to recurring partner demand. That mix of proven scale and new formulation optionality supports a Star view in the BCG Matrix, because it can keep earning royalties while opening fresh product paths.
- Proven in approved injectable drugs
- Recurring demand from partners
- Supports royalties and growth upside
Its value is less about one product and more about being embedded in partner drug delivery, which makes revenue stickier than a one-time sale. In BCG terms, that combination of steady use and expansion potential is why Captisol fits Star status.
Late-stage partnered oncology programs
Ligand has partner economics across several late-stage oncology programs, so it gets upside without funding full development risk. Cancer is still a huge market: WHO estimated 20 million new cases and 9.7 million deaths in 2022, and late-stage assets that win approval can quickly turn into major royalty and milestone streams for Company Name.
- Multiple partnered oncology shots on goal
- Low capex, high upside if approved
- Cancer demand stays structurally large
Ligand’s Stars Shine in High-Need Markets With Royalty Upside
Ligand Pharmaceuticals Incorporated’s Stars are Rylaze, Pneumosil, Vaxneuvance, Captisol, and partnered oncology assets: they sit in growing markets, with sticky demand, royalty upside, and expansion potential. Pneumococcal disease still causes about 1.5 million deaths a year worldwide, and cancer had 20 million new cases and 9.7 million deaths in 2022.
| Star | Why it fits |
|---|---|
| Rylaze | Rare leukemia need |
| Pneumosil | WHO-prequalified rollout |
| Captisol | Partner royalties |
What is included in the product
Detailed Word Document
Ligand Pharmaceuticals’ BCG Matrix maps its portfolio to guide invest, hold, or divest decisions across growth and cash flow.
Editable Excel File
One-page Ligand Pharmaceuticals BCG Matrix that quickly spots cash cows, stars, and drag—saving analysis time.
Reference Sources
Provides a traceable source trail for Ligand Pharmaceuticals data, strengthening credibility and speeding investor due diligence.
Cash Cows
Kyprolis royalties
Kyprolis is a mature multiple myeloma drug, launched in 2012, so Ligand gets a steady royalty stream rather than high growth. Amgen reported Kyprolis sales of about $1.1 billion in 2024, showing the asset is still a large, established cash generator. That profile fits a classic Cash Cow in Ligand’s BCG mix.
Nexterone royalties
Nexterone is Ligand Pharmaceuticals Incorporated's royalty stream from a mature injectable amiodarone hospital product, so demand is tied to steady inpatient and ICU use, not fast market growth. That profile fits a Cash Cow: low reinvestment, predictable royalties, and dependable cash generation for Ligand Pharmaceuticals Incorporated's portfolio.
Noxafil-IV royalties
Noxafil-IV royalties fit Cash Cows: it is an established intravenous antifungal in a mature market, so growth is limited, but it keeps producing recurring cash for Ligand Pharmaceuticals Incorporated with low reinvestment needs. That steady royalty stream supports margins even as newer programs drive most growth.
Veklury royalties
Veklury royalties fit a Cash Cow because the antiviral still throws off recurring revenue, but the COVID-19 market is mature and no longer a high-growth story. Gilead said Veklury sales were about $2.0 billion in 2024, down sharply from peak pandemic demand, so Ligand’s royalty stream is stable but slow-growing.
- Recurring royalty income
- Mature COVID demand
- Low growth, steady cash
- Cash Cow, not a Star
Teriparatide injection
Teriparatide injection fits Ligand Pharmaceuticals Incorporated’s Cash Cows: it is a mature bone-health asset in a low-growth category, so volume is usually stable rather than fast-rising. Even with generic pressure, steady osteoporosis demand can still turn into reliable royalty cash flow for Ligand, making it a classic BCG cash generator.
- Mature, low-growth bone-health product
- Stable demand supports steady cash flow
- Upside is capped by generic competition
Ligand’s Cash Cows: Steady Royalty Revenue from Mature Brands
Ligand Pharmaceuticals Incorporated’s Cash Cows are its mature royalty assets: Kyprolis, Nexterone, Noxafil-IV, Veklury, and Teriparatide injection. These brands sit in low-growth markets but still generate steady cash; Amgen said Kyprolis sales were about $1.1 billion in 2024, and Gilead said Veklury sales were about $2.0 billion in 2024.
| Asset | 2024 sales | Cash Cow fit |
|---|---|---|
| Kyprolis | $1.1B | Mature royalty stream |
| Veklury | $2.0B | Stable, low-growth cash |
Get Your Copy
Ligand Pharmaceuticals Incorporated Reference Sources
The Ligand Pharmaceuticals Incorporated BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo content, no watermarks—just the full, polished report ready for immediate use. Once purchased, the file is instantly downloadable for editing, printing, or sharing with your team.
Dogs
Zulresso
Zulresso is Ligand Pharmaceuticals Incorporated's niche postpartum depression therapy, and its uptake has stayed limited versus much larger CNS markets. In 2025, the drug still showed low growth and modest penetration, so it fits the Dog bucket in the BCG Matrix. Its small commercial footprint and narrow patient pool keep it from becoming a meaningful growth driver.
Evomela
Evomela is an older melphalan product used in a narrow multiple myeloma transplant setting, and multiple myeloma is only about 1% of all cancers. Its niche use means slow growth, while generic melphalan and other conditioning regimens keep pressure high. In Ligand Pharmaceuticals Incorporated's BCG Matrix, that fits Dogs: low share, low growth, and limited cash generation.
Duavee
Duavee, Ligand Pharmaceuticals Incorporated's menopause and osteoporosis product, sits in a mature, low-growth category, not a fast-expanding market. Its commercial scale is limited, so it does not look like a cash engine. That profile fits a Dog in the BCG Matrix.
Minnebro
Minnebro fits Ligand Pharmaceuticals Incorporated’s Dog bucket: it has modest commercial visibility, and hypertension is a huge but mature market with about 1.28 billion adults affected worldwide, which keeps growth low and competition intense.
Ligand Pharmaceuticals Incorporated does not break out Minnebro revenue separately, which signals limited scale and weak contribution versus larger assets.
- Large market, low growth
- Heavy generic and brand competition
- Limited disclosed sales visibility
Exemptia
Exemptia is a biosimilar in a price-led market, so it faces share pressure and margin squeeze by design. In Ligand Pharmaceuticals Incorporated’s BCG view, that makes it closer to a Dog if adoption stays shallow and growth stays weak. Biosimilars often win on price, not pricing power, so low uptake can cap returns fast.
- Price competition weakens margins
- Limited adoption points to Dog status
- Low growth reduces cash potential
Ligand’s Dog Assets Face Slow Growth and Heavy Pressure
Ligand Pharmaceuticals Incorporated’s Dogs are mature, low-share assets with weak growth and limited cash pull in 2025. Zulresso, Evomela, Duavee, Minnebro, and Exemptia all sit in niche or price-led markets, where generic or biosimilar pressure stays high and demand is slow to expand.
| Asset | Dog signal |
|---|---|
| Zulresso | Low uptake |
| Evomela | Niche use, generic pressure |
| Duavee | Mature, low-growth market |
| Minnebro | Limited disclosed sales |
| Exemptia | Price-led biosimilar |
Question Marks
Vivitra
Vivitra fits the "Question Mark" bucket because it is a breast-cancer biosimilar with upside from wider oncology access, but market share is still hard to win in a crowded trastuzumab space. Biosimilars can scale fast when payers and hospitals open access, yet tender wins and physician switching stay tough. That mix of high growth potential and uncertain share is classic BCG Question Mark behavior.
Bryxta
Bryxta fits the Question Mark cell because it targets oncology in a crowded biosimilar market, where early share is usually thin and wins depend on price, access, and physician uptake.
That means demand can grow, but Ligand Pharmaceuticals Incorporated must keep investing in launch, supply, and market access or Bryxta can stay niche.
In BCG terms, it has upside, but it has not yet shown the scale of a Star or Cash Cow.
Zybev
Zybev fits the Question Mark box: it targets multiple cancer indications through a biosimilar path, so the market can scale, but heavy price cuts keep share uncertain. Biosimilars in oncology often face fast erosion after launch, which makes capture of value harder even when demand is broad. For Ligand Pharmaceuticals Incorporated, this is a high-potential but still low-share asset.
Aziyo pericardial repair products
Aziyo's pericardial repair products sit in a narrow cardiac niche with room to grow, but adoption is still early versus established branded franchises. That mix of specialty demand and limited scale fits the Question Mark box in Ligand Pharmaceuticals Incorporated's BCG Matrix. The business can win if clinical use broadens, but it still needs stronger market pull and commercial traction.
- Early market development
- High growth, low share
CanGaroo envelope extracellular matrix
CanGaroo is a specialty extracellular matrix envelope for implanted devices, so it fits the Question Mark quadrant: the addressable market can grow, but Ligand Pharmaceuticals Incorporated’s penetration is still early. In device-related care, adoption tends to rise only after clinical proof and reimbursement support, so current share stays low while upside remains real.
- Specialty ECM device envelope
- Low share, growth optionality
- Best fit: Question Mark
Ligand’s Question Marks: High-Growth Assets Still Fighting for Share
Vivitra, Bryxta, and Zybev are Question Marks for Ligand Pharmaceuticals Incorporated because they sit in growing oncology biosimilar markets but still have low share and tough price pressure. CanGaroo and Aziyo also fit here: both have niche demand and real upside, yet adoption is still early. These assets need more spend and access gains before they can move toward Star status.
| Asset | BCG fit | Why |
|---|---|---|
| Vivitra | Question Mark | High growth, low share |
| Bryxta | Question Mark | Price and access driven |
| Zybev | Question Mark | Growth yes, share uncertain |
| CanGaroo | Question Mark | Early adoption, upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.